Table 1

Clinical characteristics of 67 patients with high-dose daptomycin therapy
Characteristica Daptomycin dose (mg/kg)
8 (n = 41) > 8 (n = 26) P value
Age, years 56 (18–89) 58.5 (22–87) 0.57
Male (%) 23 (56.1%) 17 (65.4%) 0.45
Weight, kg 56 (37–89) 61.5 (42–87) 0.13
Creatinine clearance, mL/min 38 (5–263) 57.5 (10–210) 0.54
Indwelling catheter useb 31 (75.6%) 16 (61.5%) 0.22
Surgery within 3 months 13 (31.7%) 10 (38.5%) 0.57
Underlying diseases
Diabetes mellitus 14 (34.1%) 8 (30.8%) 0.77
Cirrhosis of liver 1 (2.4%) 4 (15.4%) 0.14
ESRD 11 (26.8%) 7 (26.9%) 0.99
Heart failure 11 (26.8%) 11 (42.3%) 0.19
Chronic lung disease 5 (12.2%) 3 (11.5%) 0.94
Malignancy 17 (41.5%) 6 (23.1%) 0.12
Charlson index 4 (0–11) 3.5 (0–11) 0.46
Pitt bacteremia scorec 4 (0–10) 3 (0–7) 0.85
ICU stay 24 (58.5%) 17 (65.4%) 0.58
SOFA scored 7 (2–17) 8 (0–17) 0.49
Ventilator use 19 (46.3%) 14 (53.8%) 0.55
Previous anti-gram positive antibiotic
Vancomycin 28 (68.3%) 22 (84.6%) 0.14
Teicoplanin 13 (31.7%) 9 (34.6%) 0.81
Linezolid 5 (12.2%) 4 (15.4%) 0.71

a Data are median (range) for continuous variables.

b Including central venous catheter, port-A catheter, Hickman catheter, temporal pacemaker, and intra-aortic balloon pump.

c Only for bacteremic patients.

d Only for ICU patients.

ESRD, end-stage renal disease; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; VHD, valvular heart disease.

Lai et al.

Lai et al. BMC Infectious Diseases 2013 13:66   doi:10.1186/1471-2334-13-66

Open Data